XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Nature of Business (Details Narrative)
12 Months Ended
Jul. 27, 2016
shares
Jul. 17, 2016
Apr. 15, 2016
USD ($)
shares
Mar. 02, 2016
USD ($)
shares
Feb. 13, 2016
Feb. 12, 2016
USD ($)
$ / shares
shares
Feb. 12, 2016
USD ($)
$ / shares
shares
Feb. 12, 2016
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Jul. 26, 2016
$ / shares
shares
Preferred stock, par value | $ / shares                 $ 0.000001 $ 0.000001  
Number of stock options granted                 1,103,000 1,308,300  
Stock option weighted average exercise price per share | $ / shares                 $ 1.68 $ 1.25  
Stock issued during period, shares, reverse stock split, post-split 25,867                    
Common stock, par value | $ / shares           $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.000001
Stock issued during period, value, conversion of convertible securities | $                   $ 75,265  
Common stock, shares authorized 400,000,000               100,000,000 100,000,000 10,000,000,000,000
Preferred stock, shares outstanding                 0 0  
Conversion of Outstanding Stockholder Debt [Member] | Predecessor's Stockholder [Member]                      
Stock issued during period, value, conversion of convertible securities | $                 $ 150,000    
Conversion of Outstanding Stockholder Debt [Member] | GaroHAmen [Member]                      
Stock issued during period, value, conversion of convertible securities | $                 $ 350,000    
Stock Conversion from Series B Preferred Stock to Common Stock [Member]                      
Conversion of stock, shares converted 10,146,000                    
Preferred stock, shares outstanding 11,018,766                    
Conversion of stock, shares issued 10,146,000                    
Private Placement [Member] | Commissions [Member]                      
Payments of stock issuance costs | $     $ 373,778                
Momspot LLC [Member]                      
Noncontrolling interest, ownership percentage by parent           51.00% 51.00% 51.00%      
Noncontrolling interest, ownership percentage by noncontrolling owners           49.00% 49.00% 49.00%      
Interest ownership split off         51.00%            
Debt Principal Conversion to Predecessor Warrants [Member]                      
Debt conversion, original debt, amount | $             $ 665,000        
Debt Interest Conversion to Predecessor Warrants [Member]                      
Debt conversion, original debt, amount | $               $ 35,000      
Predecessor's Stockholder [Member] | Conversion of Outstanding Stockholder Debt [Member]                      
Stock issued during period, value, conversion of convertible securities | $               150,000      
Predecessor's Stockholder [Member] | Conversion of Outstanding Stockholder Debt [Member] | GaroHAmen [Member]                      
Stock issued during period, value, conversion of convertible securities | $               $ 350,000      
Series B Convertible Preferred Stock [Member]                      
Preferred stock, par value | $ / shares                 $ 0.000001 $ 0.000001  
Conversion of stock, shares converted                   10,146,000  
Preferred stock, shares outstanding                 872,766 872,766  
Conversion of stock, shares issued                   10,146,000  
Series B Preferred Stock [Member] | Private Placement [Member]                      
Class of warrant or right, number of securities called by warrants or rights           423,291 423,291 423,291      
Warrants exercise price per share | $ / shares           $ 1.25 $ 1.25 $ 1.25      
Number of stock sold during the period     420,260 913,200         2,775,000    
Sale of stock price per share | $ / shares                 $ 1.25    
Number of stock sold on gross consideration received | $     $ 525,325 $ 1,141,500         $ 3,468,750    
Stock issued during period, shares, new issues     4,108,460                
Proceeds from issuance of private placement | $     $ 4,635,575                
Proceeds from issuance of private placement, net of issuance costs | $     4,261,797                
Series B Preferred Stock [Member] | Including Conversion of Principal and Interest [Member] | Private Placement [Member]                      
Proceeds from issuance of private placement | $     5,135,575                
Proceeds from issuance of private placement, net of issuance costs | $     $ 4,761,797                
Series B Preferred Stock [Member] | Predecessor Warrants [Member]                      
Class of warrant or right, number of securities called by warrants or rights           295,945 295,945 295,945      
Warrants exercise price per share | $ / shares           $ 1.25 $ 1.25 $ 1.25      
Warrants issued for settlement and conversion of debt | $           $ 340,784          
Series B Preferred Stock [Member] | Placement Agent Warrants [Member] | Private Placement [Member]                      
Class of warrant or right, number of securities called by warrants or rights           127,346 127,346 127,346      
Warrants exercise price per share | $ / shares           $ 1.25 $ 1.25 $ 1.25      
Class of warrant or right, value of securities called by warrants or rights | $           $ 146,641 $ 146,641 $ 146,641      
Series B Preferred Stock [Member] | Reverse Stock Split [Member]                      
Stockholders' equity note, stock split, conversion ratio   15,463.7183                  
Common Stock [Member]                      
Stock issued during period, shares, reverse stock split, post-split             25,867        
Protagenic Therapeutics Inc [Member]                      
Stock issued during period, shares, conversion of series A preferred stock to series B preferred stock             297,468        
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]                      
Class of warrant or right, number of securities called by warrants or rights           295,945 295,945 295,945      
Warrants exercise price per share | $ / shares           $ 1.25 $ 1.25 $ 1.25      
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]                      
Class of warrant or right, number of securities called by warrants or rights           127,346 127,346 127,346      
Warrants exercise price per share | $ / shares           $ 1.25 $ 1.25 $ 1.25      
Protagenic Therapeutics Inc [Member] | Series B Convertible Preferred Stock [Member]                      
Common stock shares converted into preferred stock, shares               (6,612,838)      
Preferred stock, par value | $ / shares           $ 0.000001 $ 0.000001 $ 0.000001      
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member]                      
Number of stock options granted               1,807,744      
Stock option weighted average exercise price per share | $ / shares               $ 0.87      
Class of warrant or right, number of securities called by warrants or rights           3,403,367 3,403,367 3,403,367      
Warrants exercise price per share | $ / shares           $ 1.03 $ 1.03 $ 1.03      
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Private Placement [Member]                      
Class of warrant or right, number of securities called by warrants or rights           3,403,367 3,403,367 3,403,367      
Warrants exercise price per share | $ / shares           $ 1.05 $ 1.05 $ 1.05      
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Predecessor Options [Member]                      
Number of stock options granted             17,784        
Stock option weighted average exercise price per share | $ / shares             $ 1.25        
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Predecessor Warrants [Member]                      
Class of warrant or right, number of securities called by warrants or rights           295,945 295,945 295,945      
Warrants exercise price per share | $ / shares           $ 1.25 $ 1.25 $ 1.25